CYTLIMIC -cytotoxic T lvmphoctyte Immunotherapy in cancer

CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.

Japanese

News Release

Presentation at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

The results of a phase I study of Cytlimic peptide vaccine conducted at Yamaguchi University Graduate School of Medicine will be presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting being held November 7-11, 2018, in Washington, D.C.
read more

Presentation at the 77th Annual Meeting of the Japanese Cancer Association (JCA2018)

The results of a phase I study of Cytlimic peptide vaccine conducted at Yamaguchi University Graduate School of Medicine was presented at the 77th Annual Meeting of the Japanese Cancer Association held September 27-29, 2018, in Osaka.
read more

Registration of Patent on an immune-oncology medicine in Japan

Patent on an immuno-oncology medicine comprising Poly I:C and LAG-3 IgG fusion protein was registered in Japan. A novel combination adjuvant based on this invention is used in CYT001, a peptide vaccine under development in Cytlimic, to boost the vaccine efficacy.
read more

Company

Name
CYTLIMIC Inc.
Business
・Clinical trial of cancer peptide vaccines
・Nonclinical testing of cancer peptide vaccines
・Developing formulations for investigational use vaccines, stability testing
・Promoting application with pharmaceutical companies
Date established
December 16, 2016
Capital
361.5 million yen
Address
MG Meguro Ekimae Building, 15-19, Kamiosaki 2-Chome, Shinagawa-ku, Tokyo
141-0021, Japan

Board

President and CEO

Shun Doi, Ph.D.

Member of the Board

Hiromichi Kimura

CEO and Partner
Fast Track Initiative, Inc.
Member of the Board

Ken Nakamura

Solution Division General Manager
NEC Capital Solutions Limited
Member of the Board

Osamu Fujikawa

Executive Officer
NEC Corporation
Audit & Supervisory Board Member (KANSAYAKU)

Hideyuki Kumazawa

Corporate Strategy Division
NEC Corporation

Science & Technology

aaa
aaa
aaa
aaa

Downloads

2018.9.29 Update JCA2018 Poster
2018.5.29 Update ASCO 2017 Poster

Contact

お名前
御社名
メールアドレス
お問合わせ内容

PAGETOP